Product Details

• Catalog Number: T0519
• Unit Size: 1 x 10⁶ cells / 1.0 mL
• Species: Human (Homo sapiens)
• Tissue: Heart (Ventricle)
• Donor Information: Female, 33 years old, Caucasian
• Cell Type: Immortalized cardiomyocytes
• Growth Properties: Adherent, multipolar morphology
• Expression Markers: GATA-4, ACTN2, ACTN3 and MYH2
• Biosafety Level: BSL-2
• Storage Conditions: Vapor phase of liquid nitrogen or below -130°C
• Shipping Conditions: Shipped on dry ice
• Format: Cryopreserved frozen cells
• Application: Research use only (RUO)

Overview

Immortalized Human Cardiomyocytes – SV40 are derived from human heart ventricle tissue and have been genetically modified to proliferate indefinitely while retaining key cardiomyocyte characteristics. These cells exhibit high mitochondrial content, enabling efficient oxygen utilization essential for rhythmic cardiac contractions. The immortalization process allows for consistent in vitro studies related to cardiovascular physiology, drug screening, and heart disease research.These cells are a valuable model for investigating the molecular mechanisms governing cardiomyocyte apoptosis, hypertrophy, and response to mechanical stress.

Key Features and Benefits

• Long-Term Viability: Immortalized for extended culture duration without senescence.
• Reproducibility: Provides consistent results across multiple experiments.
• Ideal for Cardiac Research: Supports studies on cardiomyocyte function, drug response, and cardiac regeneration.
• Optimized Growth Conditions: Adapted to specific media and extracellular matrices for enhanced viability.
• Adherent Growth Properties: Facilitates easy handling and maintenance in culture.

Culture & Handling Guidelines

Recommended Culture Conditions

• Coating: Use PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) for optimal adhesion.
• Growth Medium: PriGrow I (TM001) supplemented with: 
  • 10% Fetal Bovine Serum (FBS)
  • 1% Penicillin/Streptomycin Solution (G255)
  • 0.5 ng/mL recombinant human EGF (Z100139)
  • 2 ng/mL recombinant human FGF2 (Z101455)
  • 5 µg/mL Insulin (TM053)
• Incubation Conditions: Maintain at 37°C in a humidified atmosphere with 5% CO₂.
• Seeding Density: 25,000 – 35,000 cells/cm²

Thawing Protocol

1. Quickly thaw cells in a 37°C water bath (maximum 2 minutes), ensuring the vial cap stays above water to prevent contamination.
2. Decontaminate the vial exterior with 70% ethanol. Perform all subsequent steps in a biosafety cabinet under aseptic conditions.
3. Transfer the thawed cell suspension into a 15 mL sterile conical tube containing 5 mL of pre-warmed complete growth media.
4. Centrifuge at 125xg for 5-7 minutes.
5. Aspirate the supernatant and gently re-suspend the cell pellet in complete growth media. Seed into a T25 culture flask.
6. Incubate under recommended conditions.

Subculturing Guidelines

1. Aspirate the spent media and rinse the cells with PBS.
2. Add 2-3 mL of pre-warmed 0.25% Trypsin-EDTA and incubate at 37°C until cells detach (approximately 2-10 minutes).
3. Neutralize trypsin by adding an equal volume of complete growth media.
4. Transfer the cell suspension to a sterile tube and centrifuge at 125xg for 5 minutes.
5. Aspirate the supernatant and re-suspend the cell pellet in fresh growth media.
6. Seed the cells at the appropriate density in new culture vessels and incubate under recommended conditions.

Cryopreservation Guidelines

• Cryopreservation Medium: Use Cryopreservation Medium (TM024) or complete growth medium supplemented with 10% DMSO.
• Freezing Procedure: Freeze at a controlled rate (-1°C per minute) before transferring to liquid nitrogen storage.

Related Products

• Recombinant Human VEGF (121aa) (E. coli) – Z102115
• Recombinant Human Beta-NGF – Z101545
• Recombinant Human TGF Beta-1 (TGFB1) – Z101555
• Recombinant Human IGF1 (E. coli) – Z100385

Disclaimer

1. This product is for research use only and not intended for therapeutic or diagnostic applications.
2. All parameters listed in the Certificate of Analysis are based on standardized testing protocols; actual results may vary based on culture conditions.
3. Customers should verify product suitability for their specific research needs before use.
4. The sale of this product may require a Material Transfer Agreement (MTA); please contact technical support for details.

References

1. Durham, Kristina K., et al. “HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner.” American Journal of Physiology-Heart and Circulatory Physiology 314.1 (2018): H31-H44.
2. Kono, Ken, et al. “Development of selective cytotoxic viral vectors for concentration of undifferentiated cells in cardiomyocytes derived from human induced pluripotent stem cells.” Scientific reports 9.1 (2019): 3630.